| Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy MP Cooper, H Foley, D Damico, M Wright, C Rhudy, A Schadler, T Platt Journal of Managed Care & Specialty Pharmacy 28 (6), 667-672, 2022 | | 2022 |
| Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy M Wright, C Rhudy, A Schadler, T Platt My disease is not “just hair loss”, 667, 2022 | | 2022 |
| MODIFIED ECHO MODEL TO INCREASE ACCESS TO HEPATITIS C TREATMENT: A HYBRID OF ECHO AND CO-MANAGEMENT BETWEEN SPECIALTY PROVIDERS AND COMMUNITY PROVIDERS. N Hooman, C Hammill, A Miller, M Starks-Baker, E Milem, M Cooper, ... HEPATOLOGY 74, 568A-569A, 2021 | | 2021 |
| HEPATITIS C TREATMENT UPTAKE IN MEDICAID INSURED PATIENTS BEFORE AND AFTER REMOVAL OF FIBROSIS STAGE AND ILLICIT DRUG USE RESTRICTIONS E Shokri, A Adekunle, N Hooman, M Cooper, K Winter, J Rosenau HEPATOLOGY 70, 930A-930A, 2019 | | 2019 |
| Treatment Uptake in Hepatitis C virus Infected Patients in Central and Eastern Kentucky RG Racho, M Abdelwadoud, JA Brown, PA Santos, CB Kuns-Adkins, ... Gastroenterology 152 (5), S1076, 2017 | | 2017 |
| Stage 3-4 Fibrosis does not guarantee access to direct-acting antivirals in patients with state-funded insurance: An analysis of a HCV referral program P Santos, R Racho, M Abdelwadoud, M Cooper, CB Kuns-Adkins, ... HEPATOLOGY 63 (1 SUPP), 406A-406A, 2016 | | 2016 |
Maribeth WrightUniversity of Kentucky Specialty PharmacyVerified email at uky.edu
